Genetic predispositions to childhood leukemia

Therapeutic Advances in Hematology

Volumn 4, Issue 4, 2013, Pages 270-290

  Stieglitz, Elliot ^a   Loh, Mignon L ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

cancer syndrome; genetic predisposition; germline; hematologic malignancy; leukemia; oncogene; tumor suppressor

Indexed keywords

EID: 84993708268     PISSN: 20406207     EISSN: 20406215     Source Type: Journal    
DOI: 10.1177/2040620713498161     Document Type: Article

References (185)

1. Ahmed M. Dokal I. (2009) Understanding aplastic anaemia/bone-marrow failure syndromes. Paediatr Child Health 19: 351–357.
2. Ahmed M. Rahman N. (2006) ATM and breast cancer susceptibility. Oncogene 25: 5906–5911.
3. Albers C. Paul D. Schulze H. Freson K. Stephens J. Smethurst P. et al. (2012) Compound inheritance of a low-frequency regulatory SNP and a rare null mutation in exon-junction complex subunit RBM8A causes TAR syndrome. Nat Genet 44: 435–439.
4. Albert M. Notarangelo L. Ochs H. (2011) Clinical spectrum, pathophysiology and treatment of the Wiskott–Aldrich syndrome. Curr Opin Hematol 18: 42–48.
5. Alter B. (2007) Diagnosis, genetics, and management of inherited bone marrow failure syndromes. Hematology Am Soc Hematol Educ Program 2007: 29–39.
6. Alter B. Giri N. Savage S. Peters J. Loud J. Leathwood L. et al. (2010) Malignancies and survival patterns in the National Cancer Institute inherited bone marrow failure syndromes cohort study. Br J Haematol 150: 179–188.
7. Aoki Y. Niihori T. Kawame H. Kurosawa K. Ohashi H. Tanaka Y. et al. (2005) Germline mutations in HRAS proto-oncogene cause Costello syndrome. Nat Genet 37: 1038–1040.
8. Aubert G. Hills M. Lansdorp P. (2012) Telomere length measurement–caveats and a critical assessment of the available technologies and tools. Mutat Res 730: 59–67.
9. Auerbach A. (2009) Fanconi anemia and its diagnosis. Mutat Res 668: 4–10.
10. Austin K. Gupta M. Jr Coats S. Tulpule A. Mostoslavsky G. Balazs A. et al. (2008) Mitotic spindle destabilization and genomic instability in Shwachman–Diamond syndrome. J Clin Invest 118: 1511–1518.
11. Avin J. (1956) The male Turner syndrome. Arch Pediatr Adolesc Med 91: 630.
12. Ball S. (2011) Diamond Blackfan anemia. Hematology Am Soc Hematol Educ Program 2011: 487–491.
13. Ballmaier M. Germeshausen M. (2011) Congenital amegakaryocytic thrombocytopenia: clinical presentation, diagnosis, and treatment. Semin Thromb Hemost 37: 673–681.
14. Bandipalliam P. (2005) Syndrome of early onset colon cancers, hematologic malignancies & features of neurofibromatosis in HNPCC families with homozygous mismatch repair gene mutations. Fam Cancer 4: 323–333.
15. Baranger L. Baruchel A. Leverger G. Schaison G. Berger C. (1990) Monosomy-7 in childhood hemopoietic disorders. Leukemia 4: 345–349.
16. Bodian M. Sheldon W. Lightwood R. (1964) Congenital hypoplasia of the exocrine pancreas. Acta Paediatr 53: 282–293.
17. Bogliolo M. Schuster B. Stoepker C. Derkunt B. Su Y. Raams A. et al. (2013) Mutations in ERCC4, encoding the DNA-repair endonuclease XPF, cause Fanconi anemia. Am J Med Genet 92: 800–806.
18. Boocock G. Morrison J. Popovic M. Richards N. Ellis L. Durie P. et al. (2003) Mutations in SBDS are associated with Shwachman–Diamond syndrome. Nat Genet 33: 97–101.
19. Boria I. Garelli E. Gazda H. Aspesi A. Quarello P. Pavesi E. et al. (2010) The ribosomal basis of Diamond–Blackfan anemia: mutation and database update. Hum Mutat 31: 1269–1279.
20. Branzei D. Foiani M. (2008) Regulation of DNA repair throughout the cell cycle. Nat Rev Mol Cell Biol 9: 297–308.
21. Brems H. Chmara M. Sahbatou M. Denayer E. Taniguchi K. Kato R. et al. (2007) Germline loss-of-function mutations in SPRED 1 cause a neurofibromatosis 1–like phenotype. Nat Genet 39: 1120–1126.
22. Bruton O. (1952) Agammaglobulinemia. Pediatrics 9: 722–728.
23. Burwick N. Coats S. Nakamura T. Shimamura A. (2012) Impaired ribosomal subunit association in Shwachman–Diamond syndrome. Blood 120: 5143–5152.
24. Cabelof D. Patel H. Chen Q. van Remmen H. Matherly L. Ge Y. et al. (2009) Mutational spectrum at GATA 1 provides insights into mutagenesis and leukemogenesis in Down syndrome. Blood 114: 2753–2763.
25. Caligiuri M. Briesewitz R. Yu J. Wang L. Wei M. Arnoczky K. et al. (2007) Novel c-CBL and CBL-b ubiquitin ligase mutations in human acute myeloid leukemia. Blood 110: 1022–1024.
26. Calvo K. Vinh D. Maric I. Wang W. Noel P. Stetler-Stevenson M. et al. (2011) Myelodysplasia in autosomal dominant and sporadic monocytopenia immunodeficiency syndrome: diagnostic features and clinical implications. Haematologica 96: 1221–1225.
27. Carney J. Maser R. Olivares H. Davis E. Le Beau M. Yates J. 3rd et al. (1998) The hMre11/hRad50 protein complex and Nijmegen breakage syndrome: linkage of double-strand break repair to the cellular DNA damage response. Cell 93: 477–486.
28. Cawthon R. Weiss R. Xu G. Viskochil D. Culver M. Stevens J. et al. (1990) A major segment of the neurofibromatosis type 1 gene: cDNA sequence, genomic structure, and point mutations. Cell 62: 193–201.
29. Cheok C. Bachrati C. Chan K. Ralf C. Wu L. Hickson I. (2005) Roles of the Bloom's syndrome helicase in the maintenance of genome stability. Biochem Soc Trans 33: 1456–1459.
30. Chitambar C. Robinson W. Glode L. (1983) Familial leukemia and aplastic anemia associated with monosomy 7. Am J Med 75: 756–762.
31. Chrzanowska K. Gregorek H. Dembowska-Bagińska B. Kalina M. Digweed M. (2012) Nijmegen breakage syndrome (NBS). Orphanet J Rare Dis 7: 13.
32. Chu W. Hickson I. (2009) RecQ helicases: multifunctional genome caretakers. Nat Rev Cancer 9: 644–654.
33. Cirstea I. Kutsche K. Dvorsky R. Gremer L. Carta C. Horn D. et al. (2009) A restricted spectrum of NRAS mutations causes Noonan syndrome. Nat Genet 42: 27–29.
34. Cohen P. (1992) Muir–Torre syndrome in patients with hematologic malignancies. Am J Hematol 40: 64–65.
35. Conley M. Broides A. Hernandez-Trujillo V. Howard V. Kanegane H. Miyawaki T. et al. (2005) Genetic analysis of patients with defects in early B-cell development. Immunol Rev 203: 216–234.
36. Cuellar-Rodriguez J. Gea-Banacloche J. Freeman A. Hsu A. Zerbe C. Calvo K. et al. (2011) Successful allogeneic hematopoietic stem cell transplantation for GATA 2 deficiency. Blood 118: 3715–3720.
37. Dale D. Person R. Bolyard A. Aprikyan A. Bos C. Bonilla M. et al. (2000) Mutations in the gene encoding neutrophil elastase in congenital and cyclic neutropenia. Blood 96: 2317–2322.
38. Diamond L. Blackfan K. (1938) Hypoplastic Anemia. Am J Dis Child 464–467.
39. Dokal I. (2011) Dyskeratosis congenita. Hematology Am Soc Hematol Educ Program 2011: 480–486.
40. Donadieu J. Leblanc T. Meunier B. Barkaoui M. Fenneteau O. Bertrand Y. et al. (2005) Analysis of risk factors for myelodysplasias, leukemias and death from infection among patients with congenital neutropenia. Experience of the French Severe Chronic Neutropenia Study Group. Haematologica 90: 45–53.
41. Draptchinskaia N. Gustavsson P. Andersson B. Pettersson M. (1999) The gene encoding ribosomal protein S 19 is mutated in Diamond–Blackfan anaemia. Nat Genet 21: 169–175.
42. Dupuis-Girod S. Medioni J. Haddad E. Quartier P. Cavazzana-Calvo M. Le Deist F. et al. (2003) Autoimmunity in Wiskott–Aldrich syndrome: risk factors, clinical features, and outcome in a single-center cohort of 55 patients. Pediatrics 111: e622–e627.
43. Dutt S. Narla A. Lin K. Mullally A. Abayasekara N. Megerdichian C. et al. (2011) Haploinsufficiency for ribosomal protein genes causes selective activation of p 53 in human erythroid progenitor cells. Blood 117: 2567–2576.
44. Ellis S. Gleizes P. (2011) Diamond Blackfan anemia: ribosomal proteins going rogue. Semin Hematol 48: 89–96.
45. Fanconi G. (1967) Familial constitutional panmyelocytopathy, Fanconi's anemia (F.A.). I. Clinical aspects. Semin Hematol 4: 233–240.
46. Friedman J. (1999) Epidemiology of neurofibromatosis type 1. Am J Med Genet 89: 1–6.
47. Furuichi Y. Kitao S. Shimamoto A. Goto M. Miller R. Smithson W. et al. (1999) Mutations in RECQL 4 cause a subset of cases of Rothmund–Thomson syndrome. Nat Genet 22: 82–84.
48. Gaidzik V. Bullinger L. Schlenk R. Zimmermann A. Rock J. Paschka P. et al. (2011) RUNX 1 mutations in acute myeloid leukemia: results from a comprehensive genetic and clinical analysis from the AML Study Group. J Clin Oncol 29: 1364–1372.
49. Gaitonde S. Boumendjel R. Angeles R. Rondelli D. (2010) Familial childhood monosomy 7 and associated myelodysplasia. J Pediat Hematol Oncol 32: e236–e237.
50. Gamis A. (2004) Acute myeloid leukemia and Down Syndrome evolution of modern therapy? State of the art review. Pediatr Blood Cancer 44: 13–20.
51. Gatti R. Becker-Catania S. Chun H. Sun X. Mitui M. Lai C. et al. (2001) The pathogenesis of ataxia-telangiectasia. Clinic Rev Allerg Immunol 20: 87–108.
52. Geddis A. (2011) Congenital amegakaryocytic thrombocytopenia. Pediatr Blood Cancer 57: 199–203.
53. German J. (1995) Bloom's syndrome. Dermatol Clin 13: 7–18.
54. German J. (1997) Bloom's syndrome. XX. The first 100 cancers. Cancer Genet Cytogenet 93: 100–106.
55. Germeshausen M. Ballmaier M. Welte K. (2006) MPL mutations in 23 patients suffering from congenital amegakaryocytic thrombocytopenia: the type of mutation predicts the course of the disease. Hum Mutat 27: 296–297.
56. Goldgar D. Easton D. Cannon-Albright L. Skolnick M. (1994) Systematic population-based assessment of cancer risk in first-degree relatives of cancer probands. J Natl Cancer I 86: 1600–1608.
57. Goto M. Miller R. Ishikawa Y. Sugano H. (1996) Excess of rare cancers in Werner syndrome (adult progeria). Cancer Epidemiol Biomarkers Prev 5: 239–246.
58. Gray M. Shen J. Kamath-Loeb A. Blank A. Sopher B. Martin G. et al. (1997) The Werner syndrome protein is a DNA helicase. Nat Genet 17: 100–103.
59. Gumy-Pause F. Wacker P. Sappino A. (2003) ATM gene and lymphoid malignancies. Leukemia 18: 238–242.
60. Gunz F. Gunz J. Chapman C. Houston I. (2009) Familial leukaemia: a study of 909 families. Scand J Haematol 15: 117–131.
61. Gustavsson P. Willig T. Haeringen A. Tchernia G. Dianzani I. Donnér M. et al. (1997) Diamond–Blackfan anaemia: genetic homogeneity for a gene on chromosome 19q13 restricted to 1.8 Mb. Nat Genet 16: 368–371.
62. Hahn C. Chong C. Carmichael C. Wilkins E. Brautigan P. Li X. et al. (2011) Heritable GATA 2 mutations associated with familial myelodysplastic syndrome and acute myeloid leukemia. Nat Genet 43: 1012–1017.
63. Hasle H. Clemmensen I. Mikkelsen M. (2000) Risks of leukaemia and solid tumours in individuals with Down's syndrome. Lancet 355: 165–169.
64. Hertzberg L. Vendramini E. Ganmore I. Cazzaniga G. Schmitz M. Chalker J. et al. (2010) Down syndrome acute lymphoblastic leukemia, a highly heterogeneous disease in which aberrant expression of CRLF 2 is associated with mutated JAK2: a report from the International BFM Study Group. Blood 115: 1006–1017.
65. Holmfeldt L. Wei L. Diaz-Flores E. Walsh M. Zhang J. Ding L. et al. (2013) The genomic landscape of hypodiploid acute lymphoblastic leukemia. Nat Genet 45: 242–252.
66. Horwitz M. (1997) The genetics of familial leukemia. Leukemia 11: 1347–1359.
67. Hsu A. Sampaio E. Khan J. Calvo K. Lemieux J. Patel S. et al. (2011) Mutations in GATA 2 are associated with the autosomal dominant and sporadic monocytopenia and mycobacterial infection (MonoMAC) syndrome. Blood 118: 2653–2655.
68. Ihara K. Ishii E. Eguchi M. Takada H. Suminoe A. Good R. et al. (1999) Identification of mutations in the c-mpl gene in congenital amegakaryocytic thrombocytopenia. Proc Natl Acad Sci U S A 96: 3132–3136.
69. Jin Y. Mazza C. Christie J. Giliani S. Fiorini M. Mella P. et al. (2004) Mutations of the Wiskott–Aldrich Syndrome Protein (WASP): hotspots, effect on transcription, and translation and phenotype / genotype correlation. Blood 104: 4010–4019.
70. Jongmans M. Kuiper R. Carmichael C. Wilkins E. Dors N. Carmagnac A. et al. (2009) Novel RUNX 1 mutations in familial platelet disorder with enhanced risk for acute myeloid leukemia: clues for improved identification of the FPD / AML syndrome. Leukemia 24: 242–246.
71. Jongmans M. van der Burgt I. Hoogerbrugge P. Noordam K. Yntema H. Nillesen W. et al. (2011) Cancer risk in patients with Noonan syndrome carrying a PTPN 11 mutation. Eur J Hum Genet 19: 870–874.
72. Kardos G. Baumann I. Passmore S. Locatelli F. Hasle H. Schultz K. et al. (2003) Refractory anemia in childhood: a retrospective analysis of 67 patients with particular reference to monosomy 7. Blood 102: 1997–2003.
73. Kazenwadel J. Secker G. Liu Y. Rosenfeld J. Wildin R. Cuellar-Rodriguez J. et al. (2012) Loss-of-function germline GATA 2 mutations in patients with MDS / AML or MonoMAC syndrome and primary lymphedema reveal a key role for GATA 2 in the lymphatic vasculature. Blood 119: 1283–1291.
74. Keane M. Ettenberg S. Nau M. Banerjee P. Cuello M. Penninger J. et al. (1999) cbl-3: a new mammalian cbl family protein. Oncogene 18: 3365.
75. Kee Y. D'Andrea A.D. (2012) Molecular pathogenesis and clinical management of Fanconi anemia. J Clin Invest 122: 3799–3806.
76. Kim S.W. Rai D. Aguiar R.C.T. (2011) Gene set enrichment analysis unveils the mechanism for the phosphodiesterase 4B control of glucocorticoid response in B-cell lymphoma. Clin Cancer Res 17: 6723–6732.
77. Kleihues P. Schäuble B. Hausen Zur A. Estève J. Ohgaki H. (1997) Tumors associated with p 53 germline mutations: a synopsis of 91 families. Am J Pathol 150: 1–13.
78. Klein C. (2011) Genetic defects in severe congenital neutropenia: emerging insights into life and death of human neutrophil granulocytes. Annu Rev Immunol 29: 399–413.
79. Klopocki E. Schulze H. Strauß G. Ott C. Hall J. Trotier F. et al. (2007) Complex inheritance pattern resembling autosomal recessive inheritance involving a microdeletion in thrombocytopenia–absent radius syndrome. Am J Med Genet 80: 232–240.
80. Komatsuzaki S. Aoki Y. Niihori T. Okamoto N. Hennekam R. Hopman S. et al. (2010) Mutation analysis of the SHOC 2 gene in Noonan-like syndrome and in hematologic malignancies. J Hum Genet 55: 801–809.
81. Korf B. (2000) Malignancy in neurofibromatosis type 1. Oncologist 5: 477–485.
82. Kostmann R. (1956) Infantile genetic agranulocytosis; agranulocytosis infantilis hereditaria. Acta Paediatr Suppl 45: 1–78.
83. Kratz C. (2005) The mutational spectrum of PTPN 11 in juvenile myelomonocytic leukemia and Noonan syndrome / myeloproliferative disease. Blood 106: 2183–2185.
84. Kratz C. Emerling B. Donovan S. Laig-Webster M. Taylor B. Thompson P. et al. (2001) Candidate gene isolation and comparative analysis of a commonly deleted segment of 7q22 implicated in myeloid malignancies. Genomics 77: 171–180.
85. Krüger L. Demuth I. Neitzel H. Varon R. Sperling K. Chrzanowska K. et al. (2007) Cancer incidence in Nijmegen breakage syndrome is modulated by the amount of a variant NBS protein. Carcinogenesis 28: 107–111.
86. Kutler D. (2003) A 20-year perspective on the International Fanconi Anemia Registry (IFAR). Blood 101: 1249–1256.
87. Lee J. Paull T. (2005) ATM activation by DNA double-strand breaks through the Mre11-Rad50-Nbs1 complex. Science 308: 551–554.
88. Levran O. Attwooll C. Henry R. Milton K. Neveling K. Rio P. et al. (2005) The BRCA1-interacting helicase BRIP 1 is deficient in Fanconi anemia. Nat Genet 37: 931–933.
89. Li F. (1969) Soft-tissue sarcomas, breast cancer, and other neoplasms : a familial syndrome? Ann Intern Med 71: 747–752.
90. Lipton J. Atsidaftos E. Zyskind I. Vlachos A. (2006) Improving clinical care and elucidating the pathophysiology of Diamond Blackfan anemia: an update from the Diamond Blackfan Anemia Registry. Pediatr Blood Cancer 46: 558–564.
91. Lipton J. Federman N. Khabbaze Y. Schwartz C. Hilliard L. Clark J. et al. (2001) Osteogenic sarcoma associated with Diamond–Blackfan anemia: a report from the Diamond–Blackfan Anemia Registry. J Pediat Hematol Oncol 23: 39–44.
92. Loh M. Vattikuti S. Schubbert S. Reynolds M. Carlson E. Lieuw K. et al. (2004) Mutations in PTPN 11 implicate the SHP-2 phosphatase in leukemogenesis. Blood 103: 2325–2331.
93. Lynch H. Boland C. Gong G. Shaw T. Lynch P. Fodde R. et al. (2006) Phenotypic and genotypic heterogeneity in the Lynch syndrome: diagnostic, surveillance and management implications. Eur J Hum Genet 14: 390–402.
94. Malinge S. Izraeli S. Crispino J. (2009) Insights into the manifestations, outcomes, and mechanisms of leukemogenesis in Down syndrome. Blood 113: 2619–2628.
95. Malkin D. Li F. Strong L. Fraumeni J. Nelson C. Kim D. et al. (1990) Germ line p 53 mutations in a familial syndrome of breast cancer, sarcomas, and other neoplasms. Science 250: 1233–1238.
96. Martinelli S. de Luca A. Stellacci E. Rossi C. Checquolo S. Lepri F. et al. (2010) Heterozygous germline mutations in the CBL tumor-suppressor gene cause a Noonan syndrome-like phenotype. Am J Med Genet 87: 250–257.
97. Massey G. (2004) Transient leukemia in newborns with Down syndrome. Pediatr Blood Cancer 44: 29–32.
98. McLean T. Ringold S. Neuberg D. Stegmaier K. Tantravahi R. Ritz J. et al. (1996) TEL/AML-1 dimerizes and is associated with a favorable outcome in childhood acute lymphoblastic leukemia. Blood 88: 4252–4258.
99. Minelli A. Maserati E. Giudici G. Tosi S. Olivieri C. Bonvini L. et al. (2001) Familial partial monosomy 7 and myelodysplasia: different parental origin of the monosomy 7 suggests action of a mutator gene. Cancer Genet Cytogenet 124: 147–151.
100. Morrell D. Cromartie E. Swift M. (1986) Mortality and cancer incidence in 263 patients with ataxia-telangiectasia. J Natl Cancer I 77: 89–92.
101. Mueller B. Pizzo P. (1995) Cancer in children with primary or secondary immunodeficiencies. J Pediatr 126: 1–10.
102. Mullighan C. Collins-Underwood J. Phillips L. Loudin M. Liu W. Zhang J. et al. (2009) Rearrangement of CRLF 2 in B-progenitor–and Down syndrome–associated acute lymphoblastic leukemia. Nat Genet 41: 1243–1246.
103. Myers K. Davies S. Shimamura A. (2013) Clinical and molecular pathophysiology of Shwachman–Diamond syndrome: an update. Hematol Oncol Clin North Am 27: 117–128.
104. Narla A. Ebert B. (2010) Ribosomopathies: human disorders of ribosome dysfunction. Blood 115: 3196–3205.
105. Niemeyer C. Kang M. Shin D. Furlan I. Erlacher M. Bunin N. et al. (2010) Germline CBL mutations cause developmental abnormalities and predispose to juvenile myelomonocytic leukemia. Nat Genet 42: 794–800.
106. Nigro J. Baker S. Preisinger A. Jessup J. Hosteller R. Cleary K. et al. (1989) Mutations in the p 53 gene occur in diverse human tumour types. Nature 342: 705–708.
107. Noonan J. (1968) Hypertelorism with Turner phenotype: a new syndrome with associated congenital heart disease. Arch Pediatr Adolesc Med 116: 373–380.
108. Ochs H. Thrasher A. (2006) The Wiskott–Aldrich syndrome. J Allergy Clin Immunol 117: 725–738.
109. Orsi L. Rudant J. Bonaventure A. Goujon-Bellec S. Corda E. Evans T. et al. (2012) Genetic polymorphisms and childhood acute lymphoblastic leukemia: GWAS of the ESCALE study (SFCE). Leukemia 26: 2561–2564.
110. Osato M. (2004) Point mutations in the RUNX1/AML1 gene: another actor in RUNX leukemia. Oncogene 23: 4284–4296.
111. Ostergaard P. Simpson M. Connell F. Steward C. Brice G. Woollard W. et al. (2011) Mutations in GATA 2 cause primary lymphedema associated with a predisposition to acute myeloid leukemia (Emberger syndrome). Nat Genet 43: 929–931.
112. Owen C. Barnett M. Fitzgibbon J. (2007) Familial myelodysplasia and acute myeloid leukaemia - a review. Br J Haematol 140: 123–132.
113. Owen C. Toze C. Koochin A. Forrest D. Smith C. Stevens J. et al. (2008) Five new pedigrees with inherited RUNX 1 mutations causing familial platelet disorder with propensity to myeloid malignancy. Blood 112: 4639–4645.
114. Pabst T. Eyholzer M. Haefliger S. Schardt J. Mueller B. (2008) Somatic CEBPA mutations are a frequent second event in families with germline CEBPA mutations and familial acute myeloid leukemia. J Clin Oncol 26: 5088–5093.
115. Pabst T. Mueller B. Zhang P. Radomska H. Narravula S. Schnittger S. et al. (2001) Dominant-negative mutations of CEBPA, encoding CCAAT / enhancer binding protein-α (C/EBPα), in acute myeloid leukemia. Nat Genet 27: 263–270.
116. Page A. Hansen A. Good R. (1963) Occurrence of leukemia and lymphoma in patients with agammaglobulinemia. Blood 21: 197–206.
117. Parikh S. Bessler M. (2012) Recent insights into inherited bone marrow failure syndromes. Curr Opin Pediatr 24: 23–32.
118. Pasquet M. Bellanné-Chantelot C. Tavitian S. Prade N. Beaupain B. LaRochelle O. et al. (2013) High frequency of GATA 2 mutations in patients with mild chronic neutropenia evolving to MonoMac syndrome, myelodysplasia, and acute myeloid leukemia. Blood 121: 822–829.
119. Pause F. Wacker P. Maillet P. Betts D. Sappino A. (2003) ATM gene alterations in childhood acute lymphoblastic leukemias. Hum Mutat 21: 554.
120. Peltomaki P. Vasen H. (2004) Mutations associated with HNPCC predisposition – update of ICG-HNPCC/INSiGHT mutation database. Dis Markers 20: 269–276.
121. Pollard J. Gatti R. (2009) Clinical radiation sensitivity with DNA repair disorders: an overview. Int J Radiat Oncol 74: 1323–1331.
122. Powell B. Jiang L. Muzny D. Treviño L. Dreyer Z. Strong L. et al. (2012) Identification of TP 53 as an acute lymphocytic leukemia susceptibility gene through exome sequencing. Pediatr Blood Cancer 60: E1–E3.
123. Preudhomme C. (2002) Favorable prognostic significance of CEBPA mutations in patients with de novo acute myeloid leukemia: a study from the Acute Leukemia French Association (ALFA). Blood 100: 2717–2723.
124. Rasmussen S. Yang W. Friedman J. (2001) Mortality in neurofibromatosis 1: an analysis using US death certificates. Am J Hum Genet 68: 1110–1118.
125. Ravindranath Y. (2004) Down syndrome and leukemia: new insights into the epidemiology, pathogenesis, and treatment. Pediatr Blood Cancer 44: 1–7.
126. Rawlings D. Witte O. (1994) Bruton's tyrosine kinase is a key regulator in B-cell development. Immunol Rev 138: 105–119.
127. Razzaque M. Nishizawa T. Komoike Y. Yagi H. Furutani M. Amo R. et al. (2007) Germline gain-of-function mutations in RAF 1 cause Noonan syndrome. Nat Genet 39: 1013–1017.
128. Reid S. Schindler D. Hanenberg H. Barker K. Hanks S. Kalb R. et al. (2006) Biallelic mutations in PALB 2 cause Fanconi anemia subtype FA-N and predispose to childhood cancer. Nat Genet 39: 162–164.
129. Renneville A. Mialou V. Philippe N. Kagialis-Girard S. Biggio V. Zabot M. et al. (2008) Another pedigree with familial acute myeloid leukemia and germline CEBPA mutation. Leukemia 23: 804–806.
130. Rey M. Duffy S. Brown J. Kennedy J. Dick J. Dror Y. et al. (2008) Enhanced alternative splicing of the FLVCR 1 gene in Diamond Blackfan anemia disrupts FLVCR 1 expression and function that are critical for erythropoiesis. Haematologica 93: 1617–1626.
131. Ricciardone M. Özçelik T. Cevher B. Özdağ H. Tuncer M. Gürgey A. et al. (1999) Human MLH 1 deficiency predisposes to hematological malignancy and neurofibromatosis type 1. Cancer Res 59: 290–293.
132. Roa B. Savino C. Richards C. (1999) Ashkenazi Jewish population frequency of the Bloom syndrome gene 2281Δ6ins7 mutation. Genet Test 3: 219–221.
133. Roberts A. Allanson J. Tartaglia M. Gelb B. (2013) Noonan syndrome. Lancet 381: 333–342.
134. Roberts A. Araki T. Swanson K. Montgomery K. Schiripo T. Joshi V. et al. (2006) Germline gain-of-function mutations in SOS 1 cause Noonan syndrome. Nat Genet 39: 70–74.
135. Rodriguez-Viciana P. Tetsu O. Tidyman W. Estep A. Conger B. Cruz M. et al. (2006) Germline mutations in genes within the MAPK pathway cause cardio-facio-cutaneous syndrome. Science 311: 1287–1290.
136. Rosenberg P. Zeidler C. Bolyard A. Alter B. Bonilla M. Boxer L. et al. (2010) Stable long-term risk of leukaemia in patients with severe congenital neutropenia maintained on G-CSF therapy. Br J Haematol 150: 196–199.
137. Sanada M. Suzuki T. Shih L. Otsu M. Kato M. Yamazaki S. et al. (2009) Gain-of-function of mutated C-CBL tumour suppressor in myeloid neoplasms. Nature 460: 904–908.
138. Sankaran V. Ghazvinian R. Do R. Thiru P. Vergilio J. Beggs A. et al. (2012) Exome sequencing identifies GATA 1 mutations resulting in Diamond–Blackfan anemia. J Clin Invest 122: 2439–2443.
139. Sarkozy A. Carta C. Moretti S. Zampino G. Digilio M. Pantaleoni F. et al. (2009) Germline BRAF mutations in Noonan, LEOPARD, and cardiofaciocutaneous syndromes: molecular diversity and associated phenotypic spectrum. Hum Mutat 30: 695–702.
140. Savage S. Bertuch A. (2010) The genetics and clinical manifestations of telomere biology disorders. Genet Med 12: 753–764.
141. Schmidt M. Dikic I. (2005) The Cbl interactome and its functions. Nat Rev Mol Cell Biol 6: 907–918.
142. Schubbert S. Zenker M. Rowe S. Böll S. Klein C. Bollag G. et al. (2006) Germline KRAS mutations cause Noonan syndrome. Nat Genet 38: 331–336.
143. Sellick G. Spendlove H. Catovsky D. Pritchard-Jones K. Houlston R. (2005) Further evidence that germline CEBPA mutations cause dominant inheritance of acute myeloid leukaemia. Leukemia 19: 1276–1278.
144. Shannon K. Turhan A. Rogers P. Kan Y. (1992) Evidence implicating heterozygous deletion of chromosome 7 in the pathogenesis of familial leukemia associated with monosomy 7. Genomics 14: 121–125.
145. Shapiro R. (2010) Malignancies in the setting of primary immunodeficiency: implications for hematologists/oncologists. Am J Hematol 86: 48–55.
146. Sherborne A. Hosking F. Prasad R. Kumar R. Koehler R. Vijayakrishnan J. et al. (2010) Variation in CDKN2A at 9p21. 3 influences childhood acute lymphoblastic leukemia risk. Nat Genet 42: 492–494.
147. Side L. Emanuel P. Taylor B. Franklin J. Thompson P. Castleberry R. et al. (1998) Mutations of the NF 1 gene in children with juvenile myelomonocytic leukemia without clinical evidence of neurofibromatosis, type 1. Blood 92: 267–272.
148. Siitonen H. Sotkasiira J. Biervliet M. Benmansour A. Capri Y. Cormier-Daire V. et al. (2008) The mutation spectrum in RECQL 4 diseases. Eur J Hum Genet 17: 151–158.
149. Smith M. Cavenagh J. Lister T. Fitzgibbon J. (2004) Mutation of CEBPA in familial acute myeloid leukemia. N Engl J Med 351: 2403–2407.
150. Song W. Sullivan M. Legare R. Hutchings S. Tan X. Kufrin D. et al. (1999) Haploinsufficiency of CBFA 2 causes familial thrombocytopenia with propensity to develop acute myelogenous leukaemia. Nat Genet 23: 166–175.
151. Stiller C. Chessells J. Fitchett M. (1994) Neurofibromatosis and childhood leukaemia/lymphoma: a population-based UKCCSG study. Br J Cancer 70: 969–972.
152. Straughen J. Ciocci S. Ye T. Lennon D. Proytcheva M. Alhadeff B. et al. (1996) Physical mapping of the Bloom syndrome region by the identification of YAC and P 1 clones from human chromosome 15 band q26. 1. Genomics 35: 118–128.
153. Stray-Pedersen A. Borresen-Dale A. Paus E. Lindman C. Burgers T. Abrahamsen T. (2007) Alpha fetoprotein is increasing with age in ataxia–telangiectasia. Eur J Paediatr Neurol 11: 375–380.
154. Sullivan K. Mullen C. Blaese R. Winkelstein J. (1994) A multiinstitutional survey of the Wiskott–Aldrich syndrome. J Pediatr 125: 876–885.
155. Tartaglia M. Martinelli S. Stella L. Bocchinfuso G. Flex E. Cordeddu V. et al. (2006) Diversity and functional consequences of germline and somatic PTPN 11 mutations in human disease. Am J Med Genet 78: 279–290.
156. Tartaglia M. Mehler E. Goldberg R. Zampino G. Brunner H. Kremer H. et al. (2001) Mutations in PTPN11, encoding the protein tyrosine phosphatase SHP-2, cause Noonan syndrome. Nat Genet 29: 465–468.
157. Tartaglia M. Niemeyer C. Fragale A. Song X. Buechner J. Jung A. et al. (2003) Somatic mutations in PTPN 11 in juvenile myelomonocytic leukemia, myelodysplastic syndromes and acute myeloid leukemia. Nat Genet 34: 148–150.
158. Taub J. (2004) Prenatal origin of GATA 1 mutations may be an initiating step in the development of megakaryocytic leukemia in Down syndrome. Blood 104: 1588–1589.
159. Thompson D. Duedal S. Kirner J. McGuffog L. Last J. Reiman A. et al. (2005) Cancer risks and mortality in heterozygous ATM mutation carriers. J Natl Cancer I 97: 813–822.
160. Tidyman W. Rauen K. (2012) The RASopathies: Syndromes of Ras / MAPK Pathway Dysregulation. Berlin: Springer.
161. Treviño L. Yang W. French D. Hunger S. Carroll W. Devidas M. et al. (2009) Germline genomic variants associated with childhood acute lymphoblastic leukemia. Nat Genet 41: 1001–1005.
162. Tsai S. Martin D. Zon L. D'Andrea A. Wong G. Orkin S. (1989) Cloning of cDNA for the major DNA-binding protein of the erythroid lineage through expression in mammalian cells. Nature 339: 446–451.
163. Tsai F. Orkin S. (1997) Transcription factor GATA-2 is required for proliferation / survival of early hematopoietic cells and mast cell formation, but not for erythroid and myeloid terminal differentiation. Blood 89: 3636–3643.
164. Väliaho J. Smith C. Vihinen M. (2006) BTKbase: the mutation database for X-linked agammaglobulinemia. Hum Mutat 27: 1209–1217.
165. Varon R. Vissinga C. Platzer M. Cerosaletti K. Chrzanowska K. Saar K. et al. (1998) Nibrin, a novel DNA double-strand break repair protein, is mutated in Nijmegen breakage syndrome. Cell 93: 467–476.
166. Villa A. Notarangelo L. Macchi P. Mantuano E. Cavagni G. Brugnoni D. et al. (1995) X–linked thrombocytopenia and Wiskott–Aldrich syndrome are allelic diseases with mutations in the WASP gene. Nat Genet 9: 414–417.
167. Vinh D. Patel S. Uzel G. Anderson V. Freeman A. Olivier K. et al. (2010) Autosomal dominant and sporadic monocytopenia with susceptibility to mycobacteria, fungi, papillomaviruses, and myelodysplasia. Blood 115: 1519–1529.
168. Vlachos A. Ball S. Dahl N. Alter B. Sheth S. Ramenghi U. et al. (2008) Diagnosing and treating Diamond Blackfan anaemia: results of an international clinical consensus conference. Br J Haematol 142: 859–876.
169. Vlachos A. Rosenberg P. Atsidaftos E. Alter B. Lipton J. (2012) Incidence of neoplasia in Diamond Blackfan anemia: a report from the Diamond Blackfan Anemia Registry. Blood 119: 3815–3819.
170. Wagner J. (2004) Germline mutations in BRCA2: shared genetic susceptibility to breast cancer, early onset leukemia, and Fanconi anemia. Blood 103: 3226–3229.
171. Wallace M. Marchuk D. Andersen L. Letcher R. Odeh H. Saulino A. et al. (1990) Type 1 neurofibromatosis gene: identification of a large transcript disrupted in three NF 1 patients. Science 249: 181–186.
172. Walne A. Dokal I. (2009) Advances in the understanding of dyskeratosis congenita. Br J Haematol 145: 164–172.
173. Wang Q. Lasset C. Desseigne F. Frappaz D. Bergeron C. Navarro C. et al. (1999) Neurofibromatosis and early onset of cancers in hMLH1-deficient children. Cancer Res 59: 294–297.
174. Wang L. Levy M. Lewis R. Chintagumpala M. Lev D. Rogers M. Plon S. (2001) Clinical manifestations in a cohort of 41 Rothmund-Thomson syndrome patients. Am J Med Genet 102: 11–17.
175. Wechsler J. Greene M. McDevitt M. Anastasi J. Karp J. Le Beau M. et al. (2002) Acquired mutations in GATA 1 in the megakaryoblastic leukemia of Down syndrome. Nat Genet 32: 148–152.
176. Weemaes C. Hustinx T. Scheres J. van Munster P. Bakkeren J. Taalman R. (1981) A new chromosomal instability disorder: the Nijmegen breakage syndrome. Acta Paediatr Scand 70: 557–564.
177. Whiteside D. McLeod R. Graham G. Steckley J. Booth K. Somerville M. et al. (2002) A homozygous germ-line mutation in the human MSH 2 gene predisposes to hematological malignancy and multiple café-au-lait spots. Cancer Res 62: 359–362.
178. Williams V. Lucas J. Babcock M. Gutmann D. Korf B. Maria B. (2009) Neurofibromatosis type 1 revisited. Pediatrics 123: 124–133.
179. Willig T. Gazda H. Sieff C. (2000) Diamond–Blackfan anemia. Curr Opin Hematol 7: 85–94.
180. Wimmer K. Etzler J. (2008) Constitutional mismatch repair-deficiency syndrome: have we so far seen only the tip of an iceberg? Hum Genet 124: 105–122.
181. Winkelstein J. Marino M. Lederman H. Jones S. Sullivan K. Burks A. et al. (2006) X-linked agammaglobulinemia. Medicine 85: 193–202.
182. Xu G. O'Connell P. Viskochil D. Cawthon R. Robertson M. Culver M. et al. (1990) The neurofibromatosis type 1 gene encodes a protein related to GAP. Cell 62: 599–608.
183. Yang J. (2009) Genome-wide interrogation of germline genetic variation associated with treatment response in childhood acute lymphoblastic leukemia. JAMA 301: 393–403.
184. Yang J. Cheng C. Devidas M. Cao X. Campana D. Yang W. et al. (2012) Genome-wide association study identifies germline polymorphisms associated with relapse of childhood acute lymphoblastic leukemia. Blood 120: 4197–4204.
185. Zaza G. Cheok M. Yang W. Panetta J. Pui C. Relling M. et al. (2005) Gene expression and thioguanine nucleotide disposition in acute lymphoblastic leukemia after in vivo mercaptopurine treatment. Blood 106: 1778–1785.